Monitoring metabolic biomarkers in ovarian cancer
Study on the Dynamic Changes of Metabolic Biomarkers and Their Prognostic Relationship in Ovarian Cancer
This study is trying to find new ways to track ovarian cancer by looking at changes in certain metabolic markers over time to help doctors better tailor treatments for patients.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Ages | 18 Years to 75 Years |
| Sex | Female |
| Sponsor | Women's Hospital School Of Medicine Zhejiang University Academic / other |
| Locations | 1 site (Hangzhou, Zhejiang) |
| Trial ID | NCT06019923 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on ovarian cancer, a highly lethal gynecological malignancy often diagnosed at advanced stages. It aims to identify new prognostic biomarkers by monitoring dynamic changes in metabolic biomarkers over time, rather than relying solely on traditional tumor markers like CA125 and HE4. By analyzing these changes, the study seeks to improve risk stratification and personalize treatment for patients, ultimately enhancing patient outcomes. The research will involve multiple time points to capture the progression of the disease more accurately.
Who should consider this trial
Good fit: Ideal candidates are women aged 18 to 75 with a pathological diagnosis of high-grade serous ovarian cancer who are newly diagnosed and have not received prior neoadjuvant therapy.
Not a fit: Patients with recurrent ovarian cancer, those who have not undergone surgical treatment, or those with a history of other malignancies may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved monitoring and personalized treatment strategies for patients with ovarian cancer.
How similar studies have performed: Previous research has indicated the potential of metabolic biomarkers in cancer prognosis, suggesting that this approach may yield valuable insights, although it is still an evolving area of study.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age between 18 and 75 years; * Pathological diagnosis of high-grade serous ovarian cancer; * Newly diagnosed ovarian cancer case without prior neoadjuvant therapy. Exclusion Criteria: * Non-primary (recurrent) patients; * Ovarian cancer patients who have not undergone surgical treatment; * Patients with a history of other malignancies.
Where this trial is running
Hangzhou, Zhejiang
- Women's Hospital School of Medicine Zhejiang University — Hangzhou, Zhejiang, China (Recruiting)
Study contacts
- Principal investigator: Hongyu Xie, phD — Women's Hospital School Of Medicine Zhejiang University
- Study coordinator: Hongyu Xie, phD
- Email: xiehongyu@zju.edu.cn
- Phone: +86-15244773429
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.